TAVR Low Risk denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for tavr low risk are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies TAVR for Low Surgical Risk as Experimental

An "experimental" or "investigational" denial means Aetna's medical policy has concluded — at the time of review — that the evidence base for TAVR in low-surgical-risk patients does not meet its threshold for proven clinical benefit. This classification can persist even after FDA approval if Aetna's internal policy has not yet been updated to reflect current evidence, or if the policy applies a narrower definition of "proven" than the broader medical community uses.

This denial is strongly appealable. TAVR in low-surgical-risk patients has received FDA approval for this indication. Professional societies including the American College of Cardiology and Society of Thoracic Surgeons have incorporated TAVR for low-risk patients into their clinical guidelines. An insurer's internal "experimental" classification does not override FDA-cleared indications, and external reviewers — who apply independent evidence standards — frequently overturn these denials.

## Federal Appeal Rights

Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair internal review and, if denied, an independent external review. External review of experimental/investigational denials is explicitly protected under federal law and most state insurance codes. The external review request window is typically within four months of the final internal denial — verify the exact date on your denial letter. Expedited external review is available when delay would seriously jeopardize your health or ability to regain maximum function.

## Appeal Process and Timeline

1. Obtain Aetna's written clinical policy for TAVR, including the version date, so you can demonstrate where its evidence review lags current regulatory and guideline status. 2. File a Level 1 internal appeal with a complete clinical package. 3. If denied, escalate to external review — independent reviewers apply current peer-reviewed evidence standards, not insurer-internal policy. 4. Consider simultaneous state insurance department complaint if the denial is clearly inconsistent with FDA approval status.

## Documentation to Gather

• FDA approval documentation: Reference to FDA's cleared indication for TAVR in low-surgical-risk patients — your cardiologist or the device manufacturer can provide this.
• Current professional society guidelines: A letter from your structural heart team citing the relevant ACC/AHA guideline recommendation for TAVR at your surgical risk level.
• Cardiothoracic and interventional cardiology team assessment: A joint letter documenting that TAVR is the guideline-concordant, non-experimental standard of care for your specific presentation.
• Peer-reviewed literature: Your physician can attach relevant published evidence supporting TAVR in low-risk patients without citing specific trial statistics.

## Criteria-Mapping Structure

Aetna's experimental denial typically lists specific evidentiary criteria it claims are unmet. Obtain the exact list from the denial letter or the applicable clinical policy bulletin. Then, in a structured table, map each criterion to the corresponding evidence your physician is providing — FDA clearance, society guideline class and level of evidence, and clinical records. Showing a direct, criterion-by-criterion rebuttal is the most effective format for both internal and external reviewers.